BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 7
• 10
• 11
• 12
• 13
• 14
• 17
• 18
• 19
• 20
• 21
• 24
• 25
• 26
• 27
• 28
• 31

• Press Releases

  Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

  March 31, 2025

   · 

  11 min read
• Press Releases

  Ozempic® (once-weekly semaglutide 1.0 mg) shown to improve walking distance and quality of life in adults with type 2 diabetes and peripheral artery disease (PAD) at ACC 2025

  March 31, 2025

   · 

  7 min read
• Press Releases

  Ozempic® (semaglutide) injection 1 mg showed improved functional outcomes and health-related quality of life in Phase 3 STRIDE trial in adults with type 2 diabetes and peripheral artery disease (PAD) presented at ACC 2025

  March 31, 2025

   · 

  8 min read
• Press Releases

  SFJ Pharmaceuticals & SERB Pharmaceuticals Present Positive Final Results from Pivotal Ph 3 REVERSE-IT Trial of Bentracimab for the Reversal of Antiplatelet Effects of Ticagrelor in Patients Requiring Surgery or Experiencing Major Bleeding

  March 31, 2025

   · 

  7 min read
• Press Releases

  Alnylam Presents New Data from the HELIOS-B Phase 3 Study of Vutrisiran in Patients with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM) at the American College of Cardiology’s Annual Scientific Session 2025

  March 31, 2025

   · 

  10 min read
• Press Releases

  Novo Nordisk A/S: Rybelsus® (oral semaglutide 14 mg) demonstrates superior reduction in cardiovascular events in the SOUL trial at ACC 2025

  March 31, 2025

   · 

  7 min read
• Press Releases

  Mineralys Therapeutics Announces Late-Breaking Data from Advance-HTN Pivotal Trial of Lorundrostat in Uncontrolled and Resistant Hypertension Presented at the American College of Cardiology’s Annual Scientific Session & Expo (ACC.25)

  March 31, 2025

   · 

  12 min read
• Press Releases

  Oral semaglutide 14 mg demonstrated superior reduction in risk of cardiovascular events in late-breaking SOUL trial presented at the American College of Cardiology

  March 31, 2025

   · 

  8 min read
• Press Releases

  Anthos Therapeutics Shares New Data from the Landmark AZALEA-TIMI 71 Study Demonstrating the Factor XI Inhibitor Abelacimab Significantly Reduced Bleeding in Patients Regardless of Age or Bleeding Risk

  March 31, 2025

   · 

  9 min read
• Press Releases

  Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179’s Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification

  March 31, 2025

   · 

  8 min read